Clinical Trial Search

Primary: Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26 — -4.79; -3.37; -3.09; -4.13 score on a scale — p=0.3202

Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events

Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58

Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants

Primary: Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria — 1; 1; 1; 2 Participants

Primary: Number of Participants With Clinically Significant AdV Infection — 3; 6; 6 Participants

Primary: Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria — 0; 9; 6; 6 Participants

Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 81.0; 86.4; 81.8; 72.7 percentage of participants

Primary: Full Field Visual Evoked Potential (VEP) — 124.8; 126.4; -2.86; -1.50 ms

Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants

Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants

Primary: Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A — -0.74; -1.05 scores on scale

Primary: Responder Rate of B-Cell Depletion at Week 4 — 87.5; 100.0; 87.5; 100.0 percentage of participants

Primary: Occurrence of Adverse Events (AEs) Across All Study Visits — 7; 10 Participants

Primary: Dose Limiting Toxicity — 0; 1; 2 Participants